Last reviewed · How we verify

NCT03238560

The Population Pharmacokinetics of Montelukast in Infants and Children

Status unknown Last updated 3 August 2017
What this trial tests

trial testing Montelukast Chewable Tablet in Asthma in 100 participants. Status unknown.

Timeline
1 October 2016
Primary endpoint
1 June 2018
1 June 2018

Quick facts

Lead sponsorShandong University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date1 October 2016
Primary completion1 June 2018
Estimated completion1 June 2018
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shandong University

Who can join

Adults 1 Month to 12, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators' aim was to evaluate the population pharmacokinetics of montelukast in infants and children and define the appropriate dose in order to optimize Montelukast treatment in this vulnerable population.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children.
    Li Q, Wang K, Shi HY, Wu YE, et al · · 2019 · cited 2× · PMID 31920289 · DOI 10.2147/dddt.s226913

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other Shandong University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03238560.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing